Document is current
Any future updates will be listed below
-
Authors
Gaylis, Norman
Both, Charlotte
Lemke, Lena
von Richter, Oliver
Yamauchi, Paul
- License Information
-
More Information
Article History
Received: 18 December 2023
Accepted: 1 February 2024
First Online: 21 March 2024
Declarations
:
: Norman Gaylis is an investigator for Alumis, AbbVie, Acelyrn, Amgen, AstraZeneca, Biogen, BMS, Gallopagos, Gilead, Horizon, IGM Sciences, LG Chem, F. Hoffmann-La Roche/Genentech and SetPoint Medical. Charlotte Both is an employee of Grünenthal GmbH. Lena Lemke is an employee of Hexal AG (A Sandoz company). Oliver von Richter is an employee of Hexal AG (A Sandoz company). Paul Yamauchi is an investigator, advisor, and/or speaker for Amgen, AbbVie, Janssen, Novartis, Boehringer Ingelheim, Lilly, Regeneron, Sanofi, LEO Pharma, Pfizer, Sun Pharma, BMS.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
